Transcriptional Dys-regulation in Anxiety and Major Depression: 5-HT1A Gene Promoter Architecture as a Therapeutic Opportunity

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|23|3738-3750

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.23, 2014-05, pp. : 3738-3750

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-HT2 ligands in the treatment of anxiety and depression

By Quesseveur Gaël   Nguyen Hai T   Gardier Alain M   Guiard Bruno P  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 11, 2012-11 ,pp. : 1701-1725

Informa Healthcare

Access to resources Recommend Favorite

Transcriptional Dysregulation: A Therapeutic Target for Polyglutamine Diseases

By  

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 5, Iss. 2, 2005-06 ,pp. : 119-127

Bentham Science Publishers

Access to resources Recommend Favorite

5-HT1B/1D antagonists and depression

By Halazy S.   Lamothe M.   Jorand-Lebrun C.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 4, 1997-04 ,pp. : 339-352

Informa Healthcare

Access to resources Recommend Favorite

5-HT 1A receptor knockout mouse as a genetic model of anxiety

By Toth M.  

European Journal of Pharmacology, Vol. 463, Iss. 1, 2003-02 ,pp. : 177-184

Elsevier

Access to resources Recommend Favorite

Transcriptional Regulation by Promoter Targeted RNAs

By  

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 12, 2009-08 ,pp. : 1079-1087

Bentham Science Publishers

Access to resources Recommend Favorite